Mylan's Fulphila Approval: Lack Of US FDA AdComm May Be A Positive For Biosimilar Industry

 
• By Sue Sutter and Anju Ghangurde
Cubes
THE US FDA DECIDED AGAINST THE NEED FOR AN ADCOMM FOR FULPHILA

More from Biosimilars

More from Biosimilars & Generics